Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts

Francesca Patriarca, Maria T. Petrucci, Sara Bringhen, Luca Baldini, Tommaso Caravita, Paolo Corradini, Alessandro Corso, Francesco Di Raimondo, Antonietta Falcone, Felicetto Ferrara, Fortunato Morabito, Pellegrino Musto, Massimo Offidani, Mario Petrini, Rita Rizzi, Gianpietro Semenzato, Patrizia Tosi, Angelo Vacca, Michele Cavo, Mario BoccadoroAntonio Palumbo

Research output: Contribution to journalArticle

Abstract

Purpose and basic procedure of the study: The availability of new targeted therapies has revolutionised the treatment of multiple myeloma (MM), for both the newly diagnosed and the relapsed and refractory settings. A panel of Italian experts provided guidelines for optimal clinical practice in the treatment of MM. Main findings and conclusions: The panel recommended that treatment should only be initiated in symptomatic patients. Autologous stem cell transplantation (ASCT) with melphalan is the treatment of choice in patients younger than 65 yr, and induction therapy including new drugs seems the most suitable preparatory regimen before ASCT. In patients who fail to achieve at least a very good partial response (VGPR) after transplant, a consolidation with a second transplant is of clinical benefit. Also, there is evidence that maintenance with thalidomide after ASCT in young patients failing to reach at least VGPR could prolong survival. In elderly patients, the combination of an alkylating drug with a novel agent should be considered as standard approach. Relapsed MM should be retreated after the reappearance of symptoms and signs of organ and tissue damage. Salvage regimens should include corticosteroids plus bortezomib, thalidomide or lenalidomide.

Original languageEnglish
Pages (from-to)93-105
Number of pages13
JournalEuropean Journal of Haematology
Volume82
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Multiple Myeloma
Stem Cell Transplantation
Thalidomide
Therapeutics
Transplants
Melphalan
Drug Combinations
Signs and Symptoms
Adrenal Cortex Hormones
Maintenance
Guidelines
Survival
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Clinical practice guidelines
  • Myeloma
  • Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Considerations in the treatment of multiple myeloma : A consensus statement from Italian experts. / Patriarca, Francesca; Petrucci, Maria T.; Bringhen, Sara; Baldini, Luca; Caravita, Tommaso; Corradini, Paolo; Corso, Alessandro; Di Raimondo, Francesco; Falcone, Antonietta; Ferrara, Felicetto; Morabito, Fortunato; Musto, Pellegrino; Offidani, Massimo; Petrini, Mario; Rizzi, Rita; Semenzato, Gianpietro; Tosi, Patrizia; Vacca, Angelo; Cavo, Michele; Boccadoro, Mario; Palumbo, Antonio.

In: European Journal of Haematology, Vol. 82, No. 2, 02.2009, p. 93-105.

Research output: Contribution to journalArticle

Patriarca, F, Petrucci, MT, Bringhen, S, Baldini, L, Caravita, T, Corradini, P, Corso, A, Di Raimondo, F, Falcone, A, Ferrara, F, Morabito, F, Musto, P, Offidani, M, Petrini, M, Rizzi, R, Semenzato, G, Tosi, P, Vacca, A, Cavo, M, Boccadoro, M & Palumbo, A 2009, 'Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts', European Journal of Haematology, vol. 82, no. 2, pp. 93-105. https://doi.org/10.1111/j.1600-0609.2008.01179.x
Patriarca, Francesca ; Petrucci, Maria T. ; Bringhen, Sara ; Baldini, Luca ; Caravita, Tommaso ; Corradini, Paolo ; Corso, Alessandro ; Di Raimondo, Francesco ; Falcone, Antonietta ; Ferrara, Felicetto ; Morabito, Fortunato ; Musto, Pellegrino ; Offidani, Massimo ; Petrini, Mario ; Rizzi, Rita ; Semenzato, Gianpietro ; Tosi, Patrizia ; Vacca, Angelo ; Cavo, Michele ; Boccadoro, Mario ; Palumbo, Antonio. / Considerations in the treatment of multiple myeloma : A consensus statement from Italian experts. In: European Journal of Haematology. 2009 ; Vol. 82, No. 2. pp. 93-105.
@article{0905a2e55e7f40cea03a7f45d4e24c27,
title = "Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts",
abstract = "Purpose and basic procedure of the study: The availability of new targeted therapies has revolutionised the treatment of multiple myeloma (MM), for both the newly diagnosed and the relapsed and refractory settings. A panel of Italian experts provided guidelines for optimal clinical practice in the treatment of MM. Main findings and conclusions: The panel recommended that treatment should only be initiated in symptomatic patients. Autologous stem cell transplantation (ASCT) with melphalan is the treatment of choice in patients younger than 65 yr, and induction therapy including new drugs seems the most suitable preparatory regimen before ASCT. In patients who fail to achieve at least a very good partial response (VGPR) after transplant, a consolidation with a second transplant is of clinical benefit. Also, there is evidence that maintenance with thalidomide after ASCT in young patients failing to reach at least VGPR could prolong survival. In elderly patients, the combination of an alkylating drug with a novel agent should be considered as standard approach. Relapsed MM should be retreated after the reappearance of symptoms and signs of organ and tissue damage. Salvage regimens should include corticosteroids plus bortezomib, thalidomide or lenalidomide.",
keywords = "Chemotherapy, Clinical practice guidelines, Myeloma, Transplantation",
author = "Francesca Patriarca and Petrucci, {Maria T.} and Sara Bringhen and Luca Baldini and Tommaso Caravita and Paolo Corradini and Alessandro Corso and {Di Raimondo}, Francesco and Antonietta Falcone and Felicetto Ferrara and Fortunato Morabito and Pellegrino Musto and Massimo Offidani and Mario Petrini and Rita Rizzi and Gianpietro Semenzato and Patrizia Tosi and Angelo Vacca and Michele Cavo and Mario Boccadoro and Antonio Palumbo",
year = "2009",
month = "2",
doi = "10.1111/j.1600-0609.2008.01179.x",
language = "English",
volume = "82",
pages = "93--105",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Considerations in the treatment of multiple myeloma

T2 - A consensus statement from Italian experts

AU - Patriarca, Francesca

AU - Petrucci, Maria T.

AU - Bringhen, Sara

AU - Baldini, Luca

AU - Caravita, Tommaso

AU - Corradini, Paolo

AU - Corso, Alessandro

AU - Di Raimondo, Francesco

AU - Falcone, Antonietta

AU - Ferrara, Felicetto

AU - Morabito, Fortunato

AU - Musto, Pellegrino

AU - Offidani, Massimo

AU - Petrini, Mario

AU - Rizzi, Rita

AU - Semenzato, Gianpietro

AU - Tosi, Patrizia

AU - Vacca, Angelo

AU - Cavo, Michele

AU - Boccadoro, Mario

AU - Palumbo, Antonio

PY - 2009/2

Y1 - 2009/2

N2 - Purpose and basic procedure of the study: The availability of new targeted therapies has revolutionised the treatment of multiple myeloma (MM), for both the newly diagnosed and the relapsed and refractory settings. A panel of Italian experts provided guidelines for optimal clinical practice in the treatment of MM. Main findings and conclusions: The panel recommended that treatment should only be initiated in symptomatic patients. Autologous stem cell transplantation (ASCT) with melphalan is the treatment of choice in patients younger than 65 yr, and induction therapy including new drugs seems the most suitable preparatory regimen before ASCT. In patients who fail to achieve at least a very good partial response (VGPR) after transplant, a consolidation with a second transplant is of clinical benefit. Also, there is evidence that maintenance with thalidomide after ASCT in young patients failing to reach at least VGPR could prolong survival. In elderly patients, the combination of an alkylating drug with a novel agent should be considered as standard approach. Relapsed MM should be retreated after the reappearance of symptoms and signs of organ and tissue damage. Salvage regimens should include corticosteroids plus bortezomib, thalidomide or lenalidomide.

AB - Purpose and basic procedure of the study: The availability of new targeted therapies has revolutionised the treatment of multiple myeloma (MM), for both the newly diagnosed and the relapsed and refractory settings. A panel of Italian experts provided guidelines for optimal clinical practice in the treatment of MM. Main findings and conclusions: The panel recommended that treatment should only be initiated in symptomatic patients. Autologous stem cell transplantation (ASCT) with melphalan is the treatment of choice in patients younger than 65 yr, and induction therapy including new drugs seems the most suitable preparatory regimen before ASCT. In patients who fail to achieve at least a very good partial response (VGPR) after transplant, a consolidation with a second transplant is of clinical benefit. Also, there is evidence that maintenance with thalidomide after ASCT in young patients failing to reach at least VGPR could prolong survival. In elderly patients, the combination of an alkylating drug with a novel agent should be considered as standard approach. Relapsed MM should be retreated after the reappearance of symptoms and signs of organ and tissue damage. Salvage regimens should include corticosteroids plus bortezomib, thalidomide or lenalidomide.

KW - Chemotherapy

KW - Clinical practice guidelines

KW - Myeloma

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=58149396179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149396179&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2008.01179.x

DO - 10.1111/j.1600-0609.2008.01179.x

M3 - Article

C2 - 19018865

AN - SCOPUS:58149396179

VL - 82

SP - 93

EP - 105

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -